

Accepted Manuscript

Title: Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma

Authors: Matteo Canale, Paola Ulivi, Francesco Giuseppe Foschi, Emanuela Scarpi, Serena De Matteis, Gabriele Donati, Giorgio Ercolani, Mario Scartozzi, Luca Faloppi, Alessandro Passardi, Emiliano Tamburini, Martina Valgiusti, Giorgia Marisi, Giovanni Luca Frassinetti, Andrea Casadei Gardini



PII: S1040-8428(17)30503-6
DOI: <https://doi.org/10.1016/j.critrevonc.2018.06.017>
Reference: ONCH 2583

To appear in: *Critical Reviews in Oncology/Hematology*

Received date: 14-11-2017
Revised date: 8-6-2018
Accepted date: 19-6-2018

Please cite this article as: Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G, Scartozzi M, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G, Frassinetti GL, Gardini AC, Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma, *Critical Reviews in Oncology / Hematology* (2018), <https://doi.org/10.1016/j.critrevonc.2018.06.017>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma

Short title: HCC survival and recurrence after radiofrequency ablation

**Matteo Canale¹, Paola Ulivi¹, Francesco Giuseppe Foschi², Emanuela Scarpi³,
Serena De Matteis¹, Gabriele Donati⁴, Giorgio Ercolani⁵⁻⁶, Mario Scartozzi⁷, Luca Faloppi⁷,
Alessandro Passardi¹, Emiliano Tamburini⁸, Martina Valgiusti⁹, Giorgia Marisi¹,
Giovanni Luca Frassinetti⁹, Andrea Casadei Gardini⁹**

¹Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

²Department of Internal Medicine, Degli Infermi Hospital, Faenza, Italy.

³Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

⁴Department of Internal Medicine, Infermi Hospital, Rimini, Italy.

⁵Department of General Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.

⁶Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

⁷Department of Medical Oncology, University Hospital Cagliari, Cagliari, Italy.

⁸Department of Medical Oncology, Infermi Hospital, Rimini, Italy.

⁹Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.

***Corresponding author:** Andrea Casadei Gardini, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014 Meldola, Italy. Tel. 39 0543 739970; Fax 39 054 739249; e-mail: andrea.casadei@irst.emr.it

Abstract

Radiofrequency ablation (RFA) is an effective local treatment for curative intent in patients with cirrhosis of the liver and hepatocellular carcinoma (HCC) with diameter < 3 cm. Several meta-analyses have shown that RFA and surgical resection are comparable in terms of their impact on overall survival. The only clinical data available on markers that are predictive of recurrence and survival after RFA treatment are based on retrospective observational studies. Prospective randomized trials are thus needed to further research in this area.

In the present review we analyzed a number of clinical factors that are considered to predict recurrence or survival in HCC patients treated with RFA. We also discussed in detail the circulating biomarkers investigated to date, together with their potential to predict prognosis and recurrence after RFA therapy.

Overall survival rates of patients with HCC are significantly affected by liver function, defined as Child-Pugh class, high baseline serum alpha-fetoprotein levels, and the presence of portosystemic collaterals. However, the development of local tumor progression does not significantly affect overall survival. This result is achieved by the

effective therapies in patients who relapse after treatment with RFA. For this reason there is an urgent need to identify new circulating biomarkers.

Keywords

Clinical outcome, radiofrequency ablation, hepatocellular carcinoma, alpha-fetoprotein, microRNAs, PD-L1, nivolumab, tremelimumab, immunotherapy, circulating miRNAs.

1. Introduction

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide ¹. Traditionally, hepatic resection and transplantation are considered the treatments of choice for patient care and have led to great improvements in morbidity, mortality and long-term survival ². However, radiofrequency ablation (RFA) is emerging as an effective local treatment for curative intent in patients with cirrhosis of the liver and HCC with a diameter < 3 cm ^{3 4}. Several meta-analyses ⁵⁻⁷ have shown that RFA and surgical resection have a comparable impact on overall (OS) and recurrence-free survival (PFS) when patients have Child-Pugh class A liver function and a lesion < 3 cm ⁸.

RFA is also used as bridge to liver transplantation, as reported by Lu et al. ⁹ and Mazzaferro et al. who demonstrated the effectiveness of this clinical approach in two large case series with very low dropout rates (6% and 0%, respectively) ¹⁰. The majority of recurrences are distant rather than local. Although several studies have been carried out to identify biomarkers that could be used to predict cancer recurrence, specific pathological patterns remain to be explored.

2. Clinical factors of RFA survival

There are still no prospective randomized studies evaluating clinical factors that are potentially predictive of recurrence and survival after RFA treatment, and findings published to date are based on retrospective observational studies. As shown in Table 1, various factors have been considered to predict survival in HCC patients treated with RFA.

With regard to liver function, patients with Child-Pugh B disease¹¹⁻¹⁴ have an increased risk of death compared to those with Child-Pugh A^{3,15-21}. The relative risk between Child Pugh B and A has been reported as around 2.26 and 5.39, respectively^{15,18}. The severity of the underlying liver disease may also represent a risk factor for HCC development and recurrence, highlighting the role of liver function in hepatocarcinogenesis. Interestingly, N'Kontchou et al. reported that the response to antiviral treatment in patients with hepatitis C virus (HCV)-derived cirrhosis, which resulted in the restoral of normal hepatic function, was associated with a dramatic decrease in HCC recurrence and a higher survival rate. In a group of 35 HCC patients with HCV-derived cirrhosis given antiviral therapy, only 10 obtained a viral response. All patient that achieved a complete response after RFA treatment had without tumor recurrence.³

With regard to liver function, other factors of poorer prognosis include reduced albumin values^{3,15,16,22-25}, increased bilirubin levels^{3,22,25,26}, and portal hypertension^{15-17,26}. However, data reported are somewhat contradictory^{3,13-17,19,21-29}, probably due to different methods of patient enrollment in the various studies. In particular, when lesion size is considered as a continuous variable, there is often no evidence of a poorer prognosis if size increases. In studies in which lesion size was dichotomized over 2 cm, results were positive, confirming that RFA is less effective for lesions > 3 cm.

The percentage of patients with non-solitary nodules treated in the various studies is an important factor. From an analysis of negative studies^{14,15,19,23,25,29}, it emerges that about 15% of enrolled patients had multiple lesions, whereas a higher number of patients with multiple nodules were recruited (> 20%) showing positive results in univariate analyses^{3,13,16,17,22,24,30}.

Concerning local tumor progression, with the exception of N'Kontchou's study³ where the hazard ratio (HR) was 0.53, patients enrolled in various studies with local tumor progression all had a poorer prognosis^{3,12,15,16}. These findings are undoubtedly correlated with radiofrequency rescue therapies which have a strong impact on survival (orthotopic liver transplantation, surgery, transarterial chemoembolization [TACE]), but are also linked to systemic therapies). Finally, parameters such as sex^{3,11-19,21-24,27-30} and hepatitis B virus (HBV)^{19,22,24-26,31} or hepatitis C virus (HCV)^{21,22,25,26} positivity do not seem to affect post-RFA survival. Moreover, as elucidated above, the response to antiviral treatments led to a lower recurrence rate and better survival.

3. Clinical factors of RFA recurrence

As previously mentioned, there are still no randomized clinical trials that have evaluated and validated clinical factors potentially predictive of post-RFA recurrence. Starting from the analysis of various studies (Table 2), the size and number of lesions are crucial parameters for predicting recurrence in the majority of cases, in contrast to what is reported for survival. This is attributable to the fact that, when more than one tumor is observed in the liver, intrahepatic metastases or multicentric HCC are more likely to occur. The few negative studies that considered these 2 parameters had patients with early-stage disease or solitary tumors. In fact, the median tumor size was around 2 cm at baseline. In this patient setting, RFA represents a promising strategy to control local

disease. Parameters such as sex and HBV or HCV positivity do not seem to affect post-treatment recurrence.

4. Circulating biomarkers of RFA recurrence

Several investigations have been carried out to identify which biomarkers markers could be useful to predict cancer recurrence, but specific pathological patterns have yet to be elucidated. We will now focus on the circulating biomarkers investigated to date and discuss their potential to predict HCC prognosis and recurrence after RFA therapy. As shown in Table 3, various factors have been considered.

5. Alpha-fetoprotein, Des- γ -carboxy prothrombin and Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein

Alpha-fetoprotein (AFP) was one of the first markers to be investigated for the diagnosis and prognosis of HCC and is still widely used in clinical practice because it is a simple and inexpensive test. However, given that AFP also has a clinical significance in patients with non-cancerous hepatic disorders, such as chronic hepatitis, cirrhosis or massive hepatic necrosis,³²⁻³⁴ it is not considered to be a completely reliable marker for HCC diagnosis. Conversely, it is believed to be predictive of HCC recurrence³⁵⁻³⁷. In a study by Siripongsakun et al., AFP levels in the pre-RFA sera of 146 patients were tested as a diagnostic tool using the same cutoff as that used to predict HCC recurrence (20 ng/mL), revealing a sensitivity of 72.2% and a specificity of 56%³⁸. Considering modified criteria of AFP ≥ 100 ng/mL and alanine aminotransferase ≥ 40 U/L, sensitivity in detecting recurrence reached 100%, with a specificity of 85%. In this setting, the role of AFP as a circulating biomarker of HCC recurrence after RFA treatment has been investigated, showing conflicting results. Pre- and post-RFA serum levels of AFP were

assessed in a large case series of HCC patients undergoing RFA, demonstrating a significant association between low circulating amounts of AFP (≤ 20 ng/mL) and time to recurrence (HR: 1.995; 95% CI, 1.476-2.697), but not a significant benefit in OS³⁹.

In another study, AFP levels ≥ 20 ng/mL proved to be a prognostic factor of early recurrence, within 6 months after treatment (HR: 3.02; 95% CI, 1.69–5.38), while an AFP level < 20 ng/mL was a marker of favorable OS (HR: 2.90; 95% CI, 1.47–5.74) in patients undergoing RFA after TACE failure⁴⁰. Moreover, a decrease of $> 20\%$ in AFP serum levels after RFA therapy strongly influenced the 5-year survival rate and tumor recurrence in a subgroup of patients with pre-treatment serum levels of AFP ≥ 100 ng/mL⁴¹.

Conversely, AFP baseline sera levels did not distinguish between 98 HCC patients who relapsed after RFA treatment and those who did not⁴². Furthermore, another study did not observe a significant correlation between AFP serum levels and short-term outcome despite a sharp decrease in this marker after RFA therapy⁴³. The role of AFP in evaluating recurrence after RFA is still subject to debate and at present there are no indications to perform it systematically. Randomized studies are needed to evaluate the real predictive role of AFP.

Des- γ -carboxy prothrombin (DCP) is a form of prothrombin produced by cancerous hepatocytes⁴⁴. As the protein is linked to neoangiogenesis, it is thought to play a role in HCC recurrence. In a case series of 1057 patients treated with RFA, DCP levels > 200 mAu/mL proved to be the strongest indicator of vascular invasion at the 1-, 3-, 5-year follow-up (HR: 3.24, 95% CI, 1.90–5.51)⁴⁵. In another study on 10-year outcome after RFA, DCP serum levels > 400 mAu/mL were found to be an independent factor related to tumor local progression⁴⁶. Of note, a recent study identified pre-ablation serum DCP levels ≥ 40 mAu/mL as an independent risk factor for OS, while the same levels post-

ablation were a risk factor for both OS (HR: 3.438; 95% CI, 1.331-8.877) and DFS (HR: 4.934; 95% CI, 2.76-8.81)³⁹. Another study found that pre-treatment DCP serum levels ≥ 40 mAu/mL were predictors of time to recurrence, as were serum levels of AFP ≥ 50 ng/mL and a prothrombin time of $< 70\%$ ⁴⁷. These data were later confirmed in other studies in which pre-treatment DCP serum levels < 100 AU/mL were identified as predictors of prolonged OS (HR: 5.49; 95% CI, 2.23-13.5) time to recurrence (HR: 6.82; 95% CI, 3.49-13.3)⁴⁸.

Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) is a fucosylated isoform of AFP with higher binding affinity to lectin Lens culinaris agglutinin⁴⁹. It is still not used in clinical practice, even though it has been shown to improve sensitivity and specificity of diagnostic tools when used in combination with AFP and DCP⁵⁰.

With regard to HCC recurrence after RFA treatment, an AFP-L3 serum level $> 15\%$ both pre- and 2 months post-RFA was a strong indicator of tumor recurrence (HR: 4.25; 95% CI, 1.42–12.74), while pre-ablation and post-ablation levels of $> 15\%$ and $\leq 15\%$, respectively, were not⁵¹. Another study comparing the clinical values of AFP-L3, AFP and DCP in the serum of 124 patients undergoing RFA showed that AFP-L3 was the most reliable marker for OS and time to recurrence⁵². Serum levels of AFP-L3 $> 10\%$ prior to RFA therapy have also proven to be an independent risk factor for local tumor progression and OS after RFA (HR: 2.94; 95% CI, 1.09–7.94)⁵³. Ueno et al. found that high levels (> 20 ng/mL) of pre-RFA AFP serum levels were predictive of poorer OS in 160 patients undergoing RFA, but only in association with high levels of Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and des- γ -carboxy prothrombin (DCP) (OR: 1.78; 95% CI, 1.16-2.72)⁵⁴, casting doubt on the accuracy of previous data that showed a significant association between AFP-L3 $\geq 10\%$ and lower

recurrence-free survival, but not between AFP and recurrence or between the three markers and recurrence ⁵⁵.

AFP, AFP-L3 and DCP are the most widely investigated circulating biomarkers in hepatocellular carcinoma and have been shown to be correlated with diagnosis and clinical outcome. Conversely, these markers have not proven very reliable in predicting recurrence after treatment for HCC, in particular RFA. Of the 3, DCP has the greatest predictive potential, but still lacks validation and an objective cut-off value.

6. Immune response biomarkers

Radiofrequency is recognized as an acute inflammation-inducing treatment because it directly destroys tumor cells, resulting in a release of tumor-associated neo-antigens (TAA). In fact, an increase in circulating markers such as histones, myeloperoxidase (MPO), inflammatory cytokines (IL-1 β , IL-6, IL-10, TNF- α), and markers of liver damage such as ALT and AST have been found in the plasma of patients 24 hours post-RFA ^{56,57}. In this setting, several immune response markers have been investigated as potential prognostic tools. Given the role of heat shock proteins (HSPs) in chaperoning tumor peptides, this class of proteins are known to have an adjuvant effect and to act as an alarm for anti-tumor T cell-mediated immunity. In a study of patients with different malignancies including HCC, pre- and post-RFA serum levels of heat-shock protein-70 (HSP70) were analyzed and correlated with outcome. An increase in HSP70 levels was transiently detectable one day after RFA treatment, and patients with a ≥ 2 -fold increase in HSP70 had better clinical outcome, possibly due to the immune response activated through the tumor peptides carried by HSPs ⁵⁸.

An *ex-vivo* study investigated TAA T-lymphocyte response after RFA treatment, detecting them in 62.3% of analyzed patients. The number of TAA-specific T-cells

post-ablation was correlated with RFS, whereas those pre-ablation were not⁵⁹. The aspartate aminotransferase-to-platelet ratio index (APRI) >1.38 was recently identified as an independent risk factor for tumor recurrence after RFA treatment (HR: 2.64, CI 95%, 1.488–4.714)⁴², while a baseline neutrophil-to-lymphocyte ratio (NLR) > 2.4 was previously associated with poorer OS but was not significantly related to relapse. In contrast, NLR > 2.4 post-RFA was found to be predictive of both OS and time to recurrence¹⁹. Moreover, an activated phenotype of NK cells was detected in the blood of patients after RFA, with a higher secretion of interferon- γ (IFN γ). Interestingly, when patients were divided into two subgroups, *i.e.* high vs. low IFN γ production and cytotoxicity, both parameters were associated with disease-free survival⁶⁰. These data suggest that the immune system response to RFA treatment and tumor-derived neo-antigens may be predictive of recurrence after RFA treatment.

Of note, a recent study associated an increase in plasma C-X-C motif chemokine 10 (CXCL10) with earlier recurrence of HCC, finding a significant correlation between time of recurrence and CXCL10 plasma levels at baseline, 1 and 7 days after RFA⁶¹. C-reactive protein (CRP), a marker of systemic inflammation related to various diseases including HCC, has also been investigated, Fujiwara et al. observing that patients with CRP pre-treatment circulating levels >0.08mg/dL had early recurrence after RFA and worse OS with respect to patients with CRP circulating levels >0.08mg/dL⁶².

A study by Shi et al. evaluated the expression of programmed-death ligand 1 (PD-L1) in patients with liver metastasis from colorectal cancer (CRCLM) before and after RFA treatment prior to surgery. The authors confirmed an increased T-cell infiltration in the tumor microenvironment of patients who underwent RFA compared to those who did not, with a higher CD8/CD4 ratio. Interestingly, they also found increased levels in PD-

L1 expression in both cancer cells and immune cells associated with RFA with respect to the tumor microenvironment of the non-RFA group. In particular, a comparison between pre- and post-ablation levels of PD-L1 in RFA patients revealed an increase in the expression of the protein in cancer cells and immune cells that was correlated with the ablation therapy⁶³. PD-L1 expression has been shown to be predictive of response to anti-PD1 antibodies⁶⁴ and a phase I/II study highlighted durable responses and good safety profiles of anti-PD-1 Nivolumab monotherapy in HCC patients, including those with HBV and HCV⁶⁵. A pilot study explored the safety and feasibility of Tremelimumab in combination with locoregional therapies aimed at promoting immunogenic tumor cell death in 18 patients (8 underwent TACE and 10 RFA) with advanced-stage HCC after refractoriness/intolerance to sorafenib. This combined therapy proved safe and, of the 10 patients evaluable for response outside of TACE or RFA treated lesions, 4 achieved confirmed partial objective response and post-treatment tumor biopsies showed immune cell infiltration in all evaluable patients.⁶⁶ To date, several trials testing safety and efficacy of immunotherapy are ongoing in advanced disease, and we think that in the future, immunotherapy can be a useful treatment in patients underwent RFA (NCT03383458).

Another study investigated clinical response in 62 HCC patients treated with RFA followed by cellular immunotherapy or RFA alone, reporting significant benefits in time to recurrence, OS and risk of local tumor progression (HR=0.136; 95% CI, 0.049–0.379) in the group that underwent the combined therapy⁶⁷. Given that tumor cells are capable of immunomodulating the tumor microenvironment, and that RFA is an immune-related treatment, it might be useful to investigate the role of immune targeted-therapy as an adjuvant to RFA. In fact, apart from local inflammation, RFA results in a release of neo-TAAs into the blood circulation that are recognized by antigen-

presenting cells (APC) and presented in secondary lymphoid organs through major histocompatibility complexes to cytotoxic T lymphocytes for priming and activation. Activated tumor-specific CTLs recognize and attack tumor cells, enhancing the anti-tumor action of RFA (Fig.1). In this setting, combining these therapeutic approaches could enhance the immune response against tumor neo-antigens, blocking the mechanism of tumor immune-editing to obtain a restored and continuous action of the cancer-immunity cycle ⁶⁸.

7. microRNAs

Interesting research has been carried out into microRNAs (miRNAs), small non-coding RNAs involved in several physiological and pathological patterns, including carcinogenesis. Several studies have identified tissue and/or circulating miRNAs for HCC diagnosis, prognosis and recurrence after locoregional treatment ^{69–72}. Conversely, few significant results are available on the relation between miRNAs and HCC recurrence after RFA treatment. Plasmatic expression of miR-122 (>100) prior to RFA was associated with poorer OS in a cohort of 57 HCC patients ⁷³, while low plasmatic levels of mir26a and 29a were correlated with worse DFS (HR=1.72; 95% CI, 1.04–2.83 and HR=1.75; 95% CI, 1.04–2.94, respectively) in patients treated with surgical resection or RFA ⁷⁴.

Epithelial-to-mesenchymal transition (EMT) has also been proposed as a resistance mechanism in HCC recurrence. Low expression levels of 200c and miR34a were found in bioptic tissue samples of 10 HCC patients who relapsed after RFA compared to 78 who did not undergo RFA, suggesting that EMT-related markers might be useful to predict poorer prognosis and aggressive local recurrence after RFA treatment ⁷⁵.

Moreover, a fascinating scenario is that involving the miRNAs as therapeutic targets; miRNA-based therapy takes advantage of two main strategies: the use of miRNA antagonists (antagomiR or antimiR) to block oncogenic miRNAs, or miRNA replacement, to restore lost function of oncosuppressor miRNAs⁷⁶. For example, the therapeutic potential of miR-122, miR26a and miR-124 has been developed in mice, and there is a need to further investigate their potential role as miRNA mimics⁷⁷. Several tissue miRNA profiles have been evaluated in relation to tumorigenesis, cancer development and metastasis⁷⁸. Disrupting the tumor cells, RFA treatment renders evaluable tissue biomarkers at circulating level, and given the rising importance of miRNAs in HCC therapeutics, finding and targeting such biomarkers in the blood circulation to predict recurrence could be very important in the management of disease. Given the acknowledged role of miRNAs in HCC diagnosis and prognosis, it would seem logical to evaluate their potential as a prognostic and therapeutic tool to predict recurrence after RFA.

8. Other studied biomarkers

A study by Ma et al. focused on γ -glutamyltranspeptidase (GGT), an enzyme related to extracellular oxidative stress, high circulating levels of which are usually found in HCC patients. Results showed that elevated serum GGT levels before RFA treatment correlated with worse OS and time to recurrence when compared with normal serum GGT levels⁷⁹. Furthermore, pre-RFA levels of serum ferritin <244 ng/mL, a marker of iron accumulation and consequent hepatic damage and carcinogenesis, were found to be predictive of better OS and longer time to recurrence¹⁸. Although serum levels of vascular endothelial growth factor (VEGF) have not shown increased levels when measured at baseline, 2 or 5 days after radiofrequency ablation⁸⁰, pre-RFA circulating

VEGF levels >240 pg/mL have been found to be associated with worse OS in HCC patients and time to recurrence ⁸¹. In this setting, further research into angiogenic factors as predictors of post-RFA recurrence are warranted given that RFA exhibits a lower angiogenic effect than TACE ⁸².

9. Uninvestigated potential biomarkers

To date, no studies have been carried out about the potential of long non-coding RNAs (lncRNAs) to predict recurrence after RFA treatment. It could be interesting to test these markers in patients undergoing RFA treatment, given that the dysregulation of many circulating lncRNAs have been correlated with HCC onset and development. For example, HULC (highly upregulated in liver cancer) has been found up-regulated in liver cancer tissues compared to non-cancerous tissues ⁸³; high expression of HOTAIR (HOX transcript antisense RNA) has been correlated with poorer prognosis and disease recurrence after surgery ⁸⁴ in HCC patients and MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) has been related to cell proliferation and migration, and it has been described as a potential diagnostic and prognostic biomarker for HCC patients ^{85,86}.

Moreover, there is a growing interest about the role of circulating microvesicles, that contain a plethora of biomarkers that could be potentially useful in cancer diagnosis, prognosis and therapeutic monitoring. Protected by the vesicle membrane, and less exposed to RNAses, intravesicular miRNAs and RNAs are more stable than circulating miRNAs and coding RNAs themselves, and, as a consequence, more reliable markers. For what concerns HCC, most of studies focused on the transcriptome of the exosomes, a particular class of microvesicles, underlying the clinical significance of several miRNAs ^{87,88}. In this setting, it could be useful to investigate the potential of circulating

microvesicles as a non-invasive tool to test new biomarkers in monitoring response to therapy and in predicting disease recurrence after RFA treatment. Techniques such as massive parallel sequencing for RNA (RNASeq) could be very useful to this aim.

As a non-invasive and low cost tool, the approach of metabolomic could be an intriguing research field. As most of compounds pass through the liver after intestine absorption, this organ is a key regulator of many circulating metabolites, empowering the possibility to relate their serum levels to liver physiopathology. The small bio-compounds (usually <1kDa molecules) profiles in chronic liver diseases including HCC have been investigated by NMR, but still there are no biomarkers able to predict time to recurrence after locoregional treatments that could be translated to clinical practice⁸⁹.

The same potential could be expected by proteomics approaches, *e.g.* mass spectrometry (MS), useful in identifying new circulating biomarkers related to liver physiopathology.

Most of studies in HCC highlighted proteomic plasmatic and serum signatures of pathways related to immunity, iron metabolism and homeostasis, apoptosis and cell degeneration/regeneration⁹⁰. These biomarkers profiles could be used in combination to AFP, AFP-L3 and DCP to empower the sensitivity in monitoring tumor progression and recurrence after RFA treatment.

In the field of liquid biopsy, increasing interest is focusing on circulating DNA (ctDNA). The analysis of this biomarker could be carried out with two principal aims: quantitative evaluation, and qualitative changes. The quantitative analyses evaluate changes in ctDNA burden in plasma/serum of patients, and there are data correlating ctDNA quantity with poorer prognosis of patient with HCC⁹¹⁻⁹³. Methylation patterns at CpG sites of oncosuppressor genes occurs frequently in HCC, and these qualitative changes are the most investigated at a circulating level^{94,95}; in particular, methylation status predicts metastastasis or recurrence of disease⁹⁶ and poor prognosis⁹⁷. More

recent studies are focusing on genome-wide methylation technologies for ctDNA, and a study by Wen et al. identified a 4 gene signature for diagnosis of small nodules (<3 cm)⁹⁸. It could be important to test this molecular profile to diagnose also early disease recurrence. Moreover, it has been proved that presence of ctDNA is predictive for portal vein invasion and extra-hepatic metastases in patients undergoing hepatectomy or liver transplantation⁹⁹. Still there are no data on the potential of ctDNA in prediction of disease recurrence of patients with HCC after RFA, and this biomarker could be a non-invasive tool to use in clinical practice to predict prognosis and recurrence in patients with HCC treated with RFA.

Conclusions

In conclusion, RFA is an effective first-line treatment modality for patients with early-stage HCC, obtaining good overall survival rates. OS is significantly affected by liver function, defined as Child-Pugh class, high baseline serum AFP level, and the presence of portosystemic collaterals, but not by long-term potentiation does New circulating biomarkers are thus urgently needed as non-invasive tools to monitor response to treatment and to detect HCC recurrence after RFA treatment.

Disclosure Statement

The authors declare no conflicts of interest.

References

1. Parkin DMM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. *Int J Cancer*. 2001;94(2):153-156. doi:10.1002/ijc.1440
2. Mazzaferro V, Chun YS, Poon RTP, et al. Liver Transplantation for Hepatocellular Carcinoma. *Ann Surg Oncol*. 2007;15(4):1001-1007. doi:10.1245/s10434-007-9559-5
3. N'Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: Long-term results and prognostic factors in 235 western patients with cirrhosis. *Hepatology*. 2009;50(5):1475-1483. doi:10.1002/hep.23181
4. Chen M-S, Li J-Q, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. *Ann Surg*. 2006;243(3):321-328. doi:10.1097/01.sla.0000201480.65519.b8
5. Chen X, Chen Y, Li Q, Ma D, Shen B, Peng C. Radiofrequency ablation versus surgical resection for intrahepatic hepatocellular carcinoma recurrence: a meta-analysis. *J Surg Res*. 2015;195(1):166-174. doi:10.1016/j.jss.2015.01.042
6. Bai H, Huangz X, Jing L, Zeng Q, Han L. The effect of radiofrequency ablation vs. liver resection on survival outcome of colorectal liver metastases (CRLM): a meta-analysis. *Hepatogastroenterology*. 2015;62(138):373-377.
7. Feng Q, Chi Y, Liu Y, Zhang L, Liu Q. Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies. *J Cancer Res Clin Oncol*. 2015;141(1):1-9. doi:10.1007/s00432-014-1708-1
8. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. *Gut*. 2014;63(5):844-855. doi:10.1136/gutjnl-2013-306627
9. Lu DSK, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. *Radiology*. 2005;234(3):954-960. doi:10.1148/radiol.2343040153
10. Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. *Ann Surg*. 2004;240(5):900-909.
11. Cho J-Y, Choi MS, Lee GS, et al. Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. *Clin Mol Hepatol*. 2016;22(4):477-486. doi:10.3350/cmh.2016.0048
12. Lin C-C, Cheng Y-T, Chen M W-T, Lin S-M. The Effectiveness of Multiple Electrode Radiofrequency Ablation in Patients with Hepatocellular Carcinoma with Lesions More than 3 cm in Size and Barcelona Clinic Liver Cancer Stage A to B2. *Liver Cancer*. 2015;5(1):8-20. doi:10.1159/000367755
13. Dan J, Zhang Y, Peng Z, et al. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. *PLoS One*. 2013;8(3):e58184. doi:10.1371/journal.pone.0058184
14. Moribata K, Tamai H, Shingaki N, Mori Y, Shiraki T, Enomoto S. Ultrasonogram of hepatocellular carcinoma is associated with outcome after

- radiofrequency ablation. *Online*. 2012;4(12):374-381.
doi:10.4254/wjh.v4.i12.374
15. Lee DH, Lee JM, Lee JY, et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. *Radiology*. 2014;270(3):900-909.
doi:10.1148/radiol.13130940
 16. Lee DH, Lee JM, Lee JY, Kim SH, Han JK, Choi BI. Radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: long-term results and prognostic factors in 168 patients with cirrhosis. *Cardiovasc Intervent Radiol*. 2014;37(3):705-715. doi:10.1007/s00270-013-0708-x
 17. Yang W, Yan K, Goldberg SN, et al. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. *World J Gastroenterol*. 2016;22(10):2993-3005. doi:10.3748/wjg.v22.i10.2993
 18. Facciorusso A, Del Prete V, Antonino M, et al. Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. *J Gastroenterol Hepatol*. 2014;29(11):1905-1910.
doi:10.1111/jgh.12618
 19. Chen T-M, Lin C-C, Huang P-T, Wen C-F. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. *J Gastroenterol Hepatol*. 2012;27(3):553-561.
doi:10.1111/j.1440-1746.2011.06910.x
 20. Giorgio A, Di Sarno A, De Stefano G, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. *Anticancer Res*. 2011;31(6):2291-2295.
 21. Takahashi H, Mizuta T, Kawazoe S, et al. Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma patients. *Hepatol Res*. 2010;40(10):997-1005. doi:10.1111/j.1872-034X.2010.00713.x
 22. Kao W-Y, Su C-W, Chiou Y-Y, et al. Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. *Radiology*. May 2017:162382.
doi:10.1148/radiol.2017162382
 23. Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc*. 2013;19(6):634-645. doi:10.1002/lt.23652
 24. Rossi S, Ravetta V, Rosa L, et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. *Hepatology*. 2011;53(1):136-147. doi:10.1002/hep.23965
 25. Kao W-Y, Chiou Y-Y, Hung H-H, et al. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. *J Clin Gastroenterol*. 2012;46(1):62-70.
doi:10.1097/MCG.0b013e31822b36cc
 26. Gao J, Wang SH, Ding XM, et al. Radiofrequency ablation for single hepatocellular carcinoma 3 cm or less as first-line treatment. *World J Gastroenterol*. 2015;21(17):5287-5294. doi:10.3748/wjg.v21.i17.5287
 27. Cui X, Wu Y, Wang Z, Liu X, Wang S, Qin C. MicroRNA-34a expression is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. *Tumour Biol*. 2015;36(5):3887-3893. doi:10.1007/s13277-014-3031-5

28. Lu L-C, Shao Y-Y, Kuo RNC, et al. Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma. *Cancer*. 2013;119(6):1210-1216. doi:10.1002/cncr.27800
29. Dal Bello B, Rosa L, Campanini N, et al. Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. *Clin Cancer Res*. 2010;16(7):2157-2166. doi:10.1158/1078-0432.CCR-09-1978
30. El-Fattah MA, Aboelmagd M, Elhamouly M. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study. *United Eur Gastroenterol J*. 2017;5(2):227-235. doi:10.1177/2050640616659024
31. Kao W-Y, Chiou Y-Y, Hung H-H, et al. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index. *Eur J Gastroenterol Hepatol*. 2011;23(6):528-536. doi:10.1097/MEG.0b013e328346d529
32. Bloomer JR, Waldmann TA, McIntire KR, Klatskin G. alpha-fetoprotein in noneoplastic hepatic disorders. *JAMA*. 1975;233(1):38-41.
33. Bloomer JR, Waldmann TA, McIntire KR, Klatskin G. Serum alpha-fetoprotein in patients with massive hepatic necrosis. *Gastroenterology*. 1977;72(3):479-492.
34. Hu K-Q, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. *Am J Gastroenterol*. 2004;99(5):860-865. doi:10.1111/j.1572-0241.2004.04152.x
35. Gomez-Rodriguez R, Romero-Gutierrez M, Artaza-Varasa T, et al. The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma. *Rev Esp Enferm Dig*. 2012;104(6):298-304.
36. Chang SK, Hlaing WW, Yu RQ, Lee TW, Ganpathi IS, Madhavan KK. Value of alpha-foetoprotein for screening of recurrence in hepatocellular carcinoma post resection. *Singapore Med J*. 2012;53(1):32-35.
37. Shirabe K, Takenaka K, Gion T, Shimada M, Fujiwara Y, Sugimachi K. Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. *J Surg Oncol*. 1997;64(2):143-146.
38. Siripongsakun S, Wei SH, Lin S, et al. Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation. *J Gastroenterol Hepatol*. 2014. doi:10.1111/jgh.12438
39. Lee S, Rhim H, Kim Y sun, Kang TW, Song KD. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma. *Liver Int*. 2016;36(4):580-587. doi:10.1111/liv.12991
40. Sohn W, Choi MS, Cho JY, et al. Role of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: Long-term outcomes and predictive factors. *Gut Liver*. 2014. doi:10.5009/gnl13356
41. Kao W-Y, Chiou Y-Y, Hung H-H, et al. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. *Clin Radiol*. 2012;67:429-436. doi:10.1016/j.crad.2011.10.009
42. Ah Chung H, Kim J-H, Hwang Y, et al. Noninvasive Fibrosis Marker Can Predict Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation. *Saudi J Gastroenterol*. 2016;22. doi:10.4103/1319-3767.173760

43. Wang N-Y, Wang C, Li W, et al. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. *Asian Pac J Cancer Prev.* 2014;15(4):1539-1544. doi:10.7314/APJCP.2014.15.4.1539
44. Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. *Gastroenterology.* 2009;137(1):110-118. doi:10.1053/j.gastro.2009.04.005
45. Asaoka Y, Tateishi R, Nakagomi R, et al. Frequency of and predictive factors for vascular invasion after radiofrequency ablation for hepatocellular carcinoma. *PLoS One.* 2014;9(11). doi:10.1371/journal.pone.0111662
46. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. *Am J Gastroenterol.* 2012;107(4):569-77; quiz 578. doi:10.1038/ajg.2011.425
47. Okuwaki Y, Nakazawa T, Shibuya A, et al. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: Risk factors and patterns. *J Gastroenterol.* 2008;43(1):71-78. doi:10.1007/s00535-007-2123-z
48. Kobayashi M, Ikeda K, Kawamura Y, et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. *Cancer.* 2009. doi:10.1002/cncr.24031
49. Kusaba T. Relationship between Lens culinaris agglutinin reactive alpha-fetoprotein and biological features of hepatocellular carcinoma. *Kurume Med J.* 1998;45(1):113-120. doi:10.1111/j.1478-3231.2005.01111.x
50. Sterling RK, Jeffers L, Gordon F, et al. Utility of Lens culinaris Agglutinin-Reactive Fraction of α -Fetoprotein and Des-Gamma-Carboxy Prothrombin, Alone or in Combination, as Biomarkers for Hepatocellular Carcinoma. *Clin Gastroenterol Hepatol.* 2009;7(1):104-113. doi:10.1016/j.cgh.2008.08.041
51. Tateishi R, Shiina S, Yoshida H, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. *Hepatology.* 2006;44(6):1518-1527. doi:10.1002/hep.21408
52. Ogawa C, Kudo M, Minami Y, Chung H, Kawasaki T. Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma. *Hepatogastroenterology.* 2008;55(85):1454-1457.
53. Takada H, Tsuchiya K, Yasui Y, et al. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular. *Cancer Med.* 2016;5(11):3111-3120. doi:10.1002/cam4.932
54. Ueno M, Hayami S, Shigekawa Y, et al. Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ≤ 5 cm: Cohort study based on serum HCC markers. *J Hepatol.* 2015;63(6):1352-1359. doi:10.1016/j.jhep.2015.07.013
55. Beppu T, Sugimoto K, Shiraki K, et al. Clinical significance of tumor markers in detection of recurrent hepatocellular carcinoma after radiofrequency ablation. *Int J Mol Med.* 2010. doi:10.3892/ijmm-00000482
56. Gu T, Ge Y, Song Y, et al. Hepatic radiofrequency ablation causes an increase of circulating histones in patients with hepatocellular carcinoma. *Scand J Clin Lab Invest.* 2015;75(7):621-627. doi:10.3109/00365513.2015.1050689
57. Erinjeri JP, Thomas CT, Samoilia A, et al. Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. *J Vasc*


- Interv Radiol.* 2013;24(8):1105-1112. doi:10.1016/j.jvir.2013.02.015
58. Haen SP, Gouttefangeas C, Schmidt D, et al. Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation. *Cell Stress Chaperones.* 2011;16(5):495-504. doi:10.1007/s12192-011-0261-y
 59. Mizukoshi E, Yamashita T, Arai K, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. *Hepatology.* 2013;57(4):1448-1457. doi:10.1002/hep.26153
 60. Zerbini A, Pilli M, Laccabue D, et al. Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response. *Gastroenterology.* 2010;138(5):1931-1942.e2. doi:10.1053/j.gastro.2009.12.051
 61. Ouyang Y, Liu K, Hao M, et al. Radiofrequency ablation-increased CXCL10 is associated with earlier recurrence of hepatocellular carcinoma by promoting stemness. *Tumor Biol.* 2016;37(3):3697-3704. doi:10.1007/s13277-015-4035-5
 62. Fujiwara N, Tateishi R, Nakagawa H, et al. Slight elevation of high-sensitivity C-reactive protein to predict recurrence and survival in patients with early stage hepatitis C-related hepatocellular carcinoma. *Hepatol Res.* 2014;645-655. doi:10.1111/hepr.12398
 63. Shi L, Chen L, Wu C, et al. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. *Clin Cancer Res.* 2016;22(5):1173-1184. doi:10.1158/1078-0432.CCR-15-1352
 64. Gao Q, Wang X-Y, Qiu S-J, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. *Clin Cancer Res.* 2009;15(3):971-979. doi:10.1158/1078-0432.CCR-08-1608
 65. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet (London, England).* 2017;389(10088):2492-2502. doi:10.1016/S0140-6736(17)31046-2
 66. Duffy AG, Ulahannan SV, Fioravanti S, et al. A pilot study of tremelimumab, a monoclonal antibody against CTLA-4, in combination with either transcatheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). *J Clin Oncol.* 2014;32(15_suppl):e15133-e15133. doi:10.1200/jco.2014.32.15_suppl.e15133
 67. Cui J, Wang N, Zhao H, et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. *Int J Cancer.* 2014;134(2):342-351. doi:10.1002/ijc.28372
 68. Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. *Immunity.* 2013;39(1):1-10. doi:10.1016/j.immuni.2013.07.012
 69. Bronte F, Bronte G, Fanale D, et al. Critical Reviews in Oncology / Hematology HepatomiRNoma : The proposal of a new network of targets for diagnosis , prognosis and therapy in hepatocellular carcinoma. 2016;97:312-321.
 70. He S, Zhang DC, Wei C. MicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis. *Clin Res Hepatol Gastroenterol.* 2015;39(4):426-434. doi:10.1016/j.clinre.2015.01.006
 71. Chauhan R, Lahiri N. Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. *Biomark Cancer.* 2016;8(Suppl 1):37-55. doi:10.4137/BIC.S34413
 72. D'Anzeo M, Faloppi L, Scartozzi M, et al. The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment. *Molecules.*

- 2014;19(5):6393-6406. doi:10.3390/molecules19056393
73. Cho HJ, Kim JK, Nam JS, et al. High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation. *Clin Biochem*. 2015;48(16-17):1073-1078. doi:10.1016/j.clinbiochem.2015.06.019
 74. Cho HJ, Kim SS, Nam JS, et al. Low levels of circulating microRNA-26a/29a as poor prognostic markers in patients with hepatocellular carcinoma who underwent curative treatment. *Clin Res Hepatol Gastroenterol*. 2016;41(2):181-189. doi:10.1016/j.clinre.2016.09.011
 75. Iwahashi S, Shimada M, Utsunomiya T, et al. Epithelial-mesenchymal transition-related genes are linked to aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation. *Cancer Lett*. 2016;375(1):47-50. doi:10.1016/j.canlet.2016.02.041
 76. Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvella M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. *J Hepatocell Carcinoma*. 2017;4:93-103. doi:10.2147/JHC.S106529
 77. Morishita A, Masaki T. miRNA in hepatocellular carcinoma. *Hepatol Res*. 2015;45(2):128-141. doi:10.1111/hepr.12386
 78. Erstad DJ, Fuchs BC, Tanabe KK. Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. *Cancer*. 2018:1-21. doi:10.1002/cncr.31257
 79. Ma H, Zhang L, Tang B, et al. γ -Glutamyltranspeptidase is a Prognostic Marker of Survival and Recurrence in Radiofrequency-Ablation Treatment of Hepatocellular Carcinoma. *Ann Surg Oncol*. 2014;21(9):3084-3089. doi:10.1245/s10434-014-3724-4
 80. Gadaleta C, Coviello M, Catino A, et al. Serum vascular endothelial growth factor concentrations in hepatocellular cancer patients undergoing percutaneously radiofrequency thermal ablation. *J Chemother*. 2004;16 Suppl 5:7-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15675467.
 81. Liakakos T, Roukos DH. Does Lymphadenectomy Improve Survival of Patients with Solid Tumors ? 2007;15(1):10434. doi:10.1245/s10434-007
 82. Tampaki M, Doumba PP, Deutsch M, Koskinas J. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights. *World J Hepatol*. 2015;7(14):1834-1842. doi:10.4254/wjh.v7.i14.1834
 83. Li C, Chen J, Zhang K, Feng B, Wang R, Chen L. Progress and Prospects of Long Noncoding RNAs (lncRNAs) in Hepatocellular Carcinoma. *Cell Physiol Biochem*. 2015;36(2):423-434. doi:10.1159/000430109
 84. Ishibashi M, Kogo R, Shibata K, et al. Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. *Oncol Rep*. 2013;29(3):946-950. doi:10.3892/or.2012.2219
 85. Lai M, Yang Z, Zhou L, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. *Med Oncol*. 2012;29(3):1810-1816. doi:10.1007/s12032-011-0004-z
 86. Liu Y-R, Tang R-X, Huang W-T, et al. Long noncoding RNAs in hepatocellular carcinoma: Novel insights into their mechanism 2015 Advances in Hepatocellular Carcinoma. *World J Hepatol*. 2015;7(28):2781-2791. doi:10.4254/wjh.v7.i28.2781
 87. Li S, Yao J, Xie M, Liu Y, Zheng M. Exosomal miRNAs in hepatocellular

- carcinoma development and clinical responses. 2018:1-9.
88. Moris D, Beal EW, Chakedis J, et al. Role of exosomes in treatment of hepatocellular carcinoma. *Surg Oncol*. 2017;26(3):219-228. doi:10.1016/j.suronc.2017.04.005
 89. Procopet B, Fischer P, Farcau O, Stefanescu H. Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease. *World J Hepatol*. 2018;10(3):371-378. doi:10.4254/wjh.v10.i3.371
 90. Kimhofer T, Fye H, Taylor-Robinson S, Thursz M, Holmes E. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: A comprehensive review. *Br J Cancer*. 2015;112(7):1141-1156. doi:10.1038/bjc.2015.38
 91. Huang Z, Hua D, Hu Y, et al. Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma. *Pathol Oncol Res*. 2012;18(2):271-276. doi:10.1007/s12253-011-9438-z
 92. Chen H, Sun L, Zheng H, Zhang Q, Jin X. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. *Pathology*. 2012;44(4):318-324. doi:10.1097/PAT.0b013e328353a24c
 93. Ren N, Qin L-X, Tu H, Liu Y-K, Zhang B-H, Tang Z-Y. The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. *J Cancer Res Clin Oncol*. 2006;132(6):399-407. doi:10.1007/s00432-005-0049-5
 94. Shen J, Wang S, Zhang Y-J, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. *Hepatology*. 2012;55(6):1799-1808. doi:10.1002/hep.25569
 95. Okajima W, Komatsu S, Ichikawa D, et al. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids. *World J Gastroenterol*. 2017;23(31):5650-5668. doi:10.3748/wjg.v23.i31.5650
 96. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. *Clin Cancer Res*. 2000;6(9):3516-3521.
 97. Chan KCA, Lai PBS, Mok TSK, et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. *Clin Chem*. 2008;54(9):1528-1536. doi:10.1373/clinchem.2008.104653
 98. Wen L, Li J, Guo H, et al. Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients. *Cell Res*. 2015;25(12):1376. doi:10.1038/cr.2015.141
 99. Ono A, Fujimoto A, Yamamoto Y, et al. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. *Cell Mol Gastroenterol Hepatol*. 2015;1(5):516-534. doi:10.1016/j.jcmgh.2015.06.009

Figure and table Legends

Fig.1. Radiofrequency ablation (RFA)-induced release of neo-tumor-associated antigens (neo-TAAs) and immune system response. **A)** RFA needle is inserted into the tumor mass. **B)** Activation of current generates frictional heating around the electrode. **C)** Destruction of tumor nodule, with subsequent release of neo-TAAs and tumor debris into the local blood circulation where inflammatory infiltrate accumulates (macrophages, natural killers, neutrophils and T lymphocytes). **D)** Neo-TAAs are drained to secondary lymphoid organs through afferent lymphatic vessels, stimulating immature dendritic cells to activate T cells. **E)** Activated tumor-specific T-cells enter the blood circulation and kill tumor cells. Immune co-stimulators and immune checkpoint inhibitors have been proposed as potential adjuvant therapies with curative intent ILs, interleukins.



Tables:

Table 1. Graphical aspect on overall survival of HCC patients after RFA. For Material and methods show supplementary materials




Table 2. Graphical aspect on recurrence free survival of HCC patients after RFA. For Material and methods show supplementary materials




Table 3. Circulating biomarkers investigated to date for HCC recurrence after RFA

Circulating biomarker	Category	Application	RFA recurrence	Reference
AFP	Serum glycoprotein	Diagnosis and prognosis	<20ng/mL post-RFA treatment (P<0.001)	39
AFP-L3	Serum glycoprotein	Diagnosis and prognosis	≥20 ng/mL levels predicted early recurrence (HR 3.02) <20ng/mL levels predicted better OS (HR 2.9)	40
			>100 ng/mL levels reached 100% sensitivity and 85% specificity in predicting recurrence	38
			>20% decrease starting by >100ng/mL pre-RFA treatment associated with better DFS and OS	41
			Pre-treatment levels did not discriminate between recurrent and non-recurrent patients	42
			>20ng/mL levels only predicted OS in association with AFP-L3 and DCP	44
			>15% pre- and post-RFA was an indicator of HCC recurrence (HR 4.25)	48
DCP	Enzyme secreted by cancerous hepatocytes	Diagnosis and prognosis	<40 mAU/mL post-RFA predictor of better OS (P=0.002) and RFS (P<0.001)	39
			More reliable than AFP in predicting DFS and OS	49
			>10% pre-RFA was an indicator of tumor progression and poor survival; HR 2.94	²⁸ 50

			>400 mAU/mL levels were predictors of tumor local progression	53
APRI	Aminotransferase-to-platelet ratio index		≥ 40 mAU/mL levels were predictors for OS and DFS	39
			≥ 40 mAU/mL levels were predictive of intrahepatic distant recurrence (p=0.006)	54
			<100 mAU /mL levels were associated with prolonged OS (HR 5.49) and RFS (HR 6.82)	55
			>1.38 was predictive of tumor recurrence (HR 2.64)	42
NLR	Neutrophil-to-lymphocyte ratio	Tumor inflammation compared to host immunity	>2.4 was a predictor of recurrence (p=0.01) and poorer OS (p=0.006)	19
GGT	Serum biomarker	Extracellular oxidative stress	OS survival (P=0.001) and recurrence (P=0.001)	76
Ferritin	Serum biomarker	Iron accumulation and liver damage	<244 ng/mL levels predicted better OS (P<0.001) and a longer time-to-recurrence (P<0.001)	18
miR122	Serum miRNA	Related to hepatocarcinogenesis	Expression >100 predicted poorer OS (P=0.042)	73
mir26a, miR29a	Serum miRNA	Tumor suppressors in carcinogenesis and metastasis	Low expression predicted poorer DFS (HR 1.72, HR 1.75)	74
miR200c, miR34a	Tissue miRNA	EMT inhibitors	Low expression associated with relapse (P=0.04)	75

HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; HR, hazard ratio; RFS, relapse-free survival; OS, overall survival; DFS, disease-free survival; AFP, alpha-fetoprotein; AFP-L3: lens culinaris agglutinin-reactive fraction of AFP; DCP: des- γ -carboxy prothrombin; GGT, γ -glutamyl transpeptidase; EMT, epithelial-mesenchymal transition